智通财经APP讯， 开润股份(300577.SZ)发布公告，公司全资子公司滁州米润科技有限公司(以下简称"滁 州米润""受让方")拟以自有资金或自筹资金人民币3.36亿元收购泰安玖安投资服务合伙企业(有限合伙) (以下简称"玖安投资")持有的上海嘉乐股份有限公司(以下简称"上海嘉乐""嘉乐股份""标的公司")24%股 份;拟以自有资金或自筹资金人民币5,812.86万元收购嘉兴弘之帆股权投资合伙企业(有限合伙)(以下简 称"弘之帆投资")持有的上海嘉乐4.1520%股份。本次交易完成后，上海嘉乐将成为公司全资子公司。 本次收购股权完成后，上海嘉乐将成为公司全资子公司，有助于增强公司整体战略协同与资源整合，提 高运营和决策管理效率，降低管理成本，实现公司整体资源的优化配置，符合公司长期发展战略。 ...

每经AI快讯，12月29日，桂冠电力（600236）(600236.SH)公告称，公司拟以现金方式收购控股股东大 唐集团持有的大唐西藏能源开发有限公司和大唐ZDN清洁能源开发有限公司100%股权，交易总价为 20.25亿元。该交易构成关联交易，但不构成重大资产重组。交易完成后，将提升公司市场竞争力，加 快推进高质量发展。 ...

根据符合《证券法》规定的评估机构北京国融兴华资产评估有限责任公司出具的《山西高速集团股份有 限公司拟收购股权所涉及山西交通实业发展集团有限公司股东全部权益价值资产评估报告》（国融兴华 评报字[2025]第500010号，简称"《资产评估报告》"），截至评估基准日2025年7月31日，在持续经营 条件下，标的公司的股东全部权益账面价值为38,908.91万元，评估价值为50,314.41万元，其中苏汽集团 持有的实业集团15%股东部分权益价值为7,547.16万元。以上述评估值为基础，交易双方协商确定标的 公司股权转让价款为7,480万元。 格隆汇12月29日丨山西高速(000755.SZ)公布，苏汽集团基于自身业务发展因素考虑，拟转让所持实业 集团15%股权，公司拟以现金收购苏汽集团持有的实业集团15%股权。本次交易完成后，实业集团将成 为公司的参股公司，不纳入公司合并报表范围，公司与山西交通控股集团有限公司（简称"山西交控集 团"）、招商局公路网络科技控股股份有限公司（简称"招商公路"）共同持有实业集团股权。 ...

中国证监会网站8月31日公布的中国证券监督管理委员会宁夏监管局行政处罚决定书(〔2020〕1号)显 示，2018年10月，江苏金通灵流体机械科技股份有限公司(以下简称"金通灵")控股股东、实际控制人季 某及一致行动人季某东所持上市公司股份100%质押，出现流动性困难，开始筹划转让上市公司股权。 季某通过金通灵上海办事处联系到恒泰华盛资产管理有限公司(以下简称"恒泰华盛")郝某等人，郝某联 系了陕西金资基金管理有限公司(以下简称"陕金资")总经理万某。后陕金资、陕西金融资产管理股份有 限公司(陕金资控股股东，以下简称"陕金融")与金通灵相互进行了解、商谈，但未能对转让股权事项取 得一致意见。2018年11月12日，万某等人到中陕核工业集团公司(陕金融股东，以下简称"中陕核")商谈 业务，向中陕核时任总会计师范某提到金通灵控股股东转让股权一事，有意由中陕核出资成立基金，通 过基金收购金通灵控股权。 2018年11月14日，范某、中陕核金融发展部部长哈某新等人与中陕核下属投资公司相关人员讨论收购金 通灵控股权事宜，形成可以推进的意见。2018年11月20日，金通灵、中陕核、陕金资、恒泰华盛相关人 员在中陕核会谈，签 ...

极兔速递-W(01519)发布公告，于2025年12月25日，卖方、New Exploration Investment、Jet Global、 Onwing Global与公司订立股份转让协议I，据此，Onwing Global(公司附属公司)同意收购且卖方及New Exploration Investment同意出售Jet Global合共约36.99%(按已转换基准)的股权，总对价最高为9.50亿美 元。 于2025年12月25日，eWTP、JNT Express KSA、J&T KSA与公司订立股份转让协议II，据此，J&T KSA(公司非全资附属公司)同意收购且eWTP同意出售JNT Express KSA合共约46.55%的股权，总对价最 高约为1.06亿美元。 于本公告日期，公司间接拥有JNT Express KSA约53.45%权益，而JNT Express KSA为公司的非全资附属 公司。建议JNT Express KSA转让完成后，JNT Express KSA将由公司间接全资拥有且将继续为公司的附 属公司，而JNT Express KSA的财务业绩将继续并入公司的财务报表中。 建议转让拟 ...

Group 1 - The company has entered into a share transfer agreement with New Exploration Investment, Jet Global, and Onwing Global, where Onwing Global will acquire approximately 36.99% of Jet Global's shares for a total consideration of up to $950 million [1] - As of the announcement date, the company indirectly holds about 63.81% of Jet Global's equity before the conversion of convertible notes, which will reduce to approximately 59.44% after the conversion [1] - Jet Global will continue to be a subsidiary of the company, and its financial performance will be consolidated into the company's financial statements [1] Group 2 - A separate share transfer agreement has been established with eWTP, JNT Express KSA, and J&T KSA, where J&T KSA will acquire approximately 46.55% of JNT Express KSA's shares for a total consideration of up to $106 million [2] - The company currently holds about 53.45% of JNT Express KSA's equity, and post-transfer, JNT Express KSA will be indirectly wholly owned by the company [2] - The proposed transfers aim to optimize the company's capital structure and create favorable conditions for long-term development, while also extending payment obligations to enhance financial flexibility [2]

Group 1 - Green Leaf Pharmaceutical (02186.HK) announced a share transfer agreement involving Nanjing Green Leaf, a subsidiary, where an investor will transfer 25% of its stake for RMB 1.086 billion to Nanjing Xinshi [1] - Nanjing Xinshi is a limited partnership, with Shandong Green Leaf, a wholly-owned subsidiary, acquiring approximately 33.2% of its partnership interests for RMB 200 million [1] - The remaining interests in Nanjing Xinshi are held by China Cinda (approximately 66.4%) and two general partners, Hangzhou Xinshi and Yantai Hexin, each holding about 0.2% [1] Group 2 - Nanjing Xinshi has the right to request Yantai Green Leaf to repurchase its stake in Nanjing Green Leaf under a share option agreement upon the occurrence of specified events [2] - Yantai Green Leaf has the option to require China Cinda to sell its interests in Nanjing Xinshi, and must also acquire Hangzhou Xinshi's partnership interests if it exercises this option [2] - Following the completion of the share transfer, Nanjing Xinshi will secure bank financing of up to RMB 648 million, with Yantai Green Leaf and Shenzhen Green Leaf providing guarantees for this financing [2]

Group 1 - Green Leaf Pharmaceutical (02186) announced a share transfer agreement involving Nanjing Green Leaf, a subsidiary, where an investor will transfer 25% of its stake for RMB 1.086 billion to Nanjing Xinshi [1] - Nanjing Xinshi, a limited partnership, will acquire the stake, while Shandong Green Leaf, a wholly-owned subsidiary, subscribed to approximately 33.2% of Nanjing Xinshi's partnership interests for RMB 200 million [1] - The remaining interests in Nanjing Xinshi are held by China Cinda with about 66.4% and by Hangzhou Xinshi and Yantai Hexin as general partners, each holding approximately 0.2% [1] Group 2 - Following the share transfer, Nanjing Xinshi is expected to secure bank financing of up to RMB 648 million, with guarantees provided by Yantai Green Leaf and Shenzhen Green Leaf [2] - The purpose of the transaction is to introduce third-party investors to provide financing and support for the payment of the share transfer, ensuring timely access to necessary funds for acquiring the 25% stake in Nanjing Green Leaf [2] - Nanjing Green Leaf and its subsidiaries primarily engage in the production and sale of pharmaceuticals, focusing on cancer treatment [2]

Core Viewpoint - Green Leaf Pharmaceutical (02186) announced a share transfer agreement involving its subsidiary, Nanjing Green Leaf, where an investor will transfer 25% of its equity to Nanjing Xinshi for RMB 1.086 billion, aimed at securing financing and support for the company’s operations in the oncology sector [1][2]. Group 1: Share Transfer Agreement - The investor, Shenzhen Green Leaf Private Equity Investment Fund, will transfer 25% of its stake in Nanjing Green Leaf to Nanjing Xinshi for RMB 1.086 billion [1]. - Nanjing Xinshi, a limited partnership, will hold approximately 33.2% of the partnership interests after a previous investment of RMB 200 million by Shandong Green Leaf [1]. - The remaining interests in Nanjing Xinshi are held by China Cinda (66.4%) and other partners [1]. Group 2: Financing and Obligations - Following the share transfer, Nanjing Xinshi is expected to secure bank financing of up to RMB 648 million, with guarantees provided by Shandong Green Leaf and Shenzhen Green Leaf [2]. - Nanjing Xinshi is required to make semi-annual distributions to China Cinda as per the partnership agreement [2]. - The agreements include options for Shandong Green Leaf to acquire interests from China Cinda and other partners under specified conditions [2]. Group 3: Business Focus - Nanjing Green Leaf and its subsidiaries primarily engage in the production and sale of pharmaceuticals, focusing on oncology treatments [2].

Group 1 - The company has signed a share acquisition agreement to acquire 96.15% of Zhejiang Xianglong Machinery Co., Ltd. for a total price of 2,403.84 million yuan [2][3] - The acquisition was approved during the 20th meeting of the sixth board of directors held on October 28, 2025 [2] - Following the completion of the acquisition, Zhejiang Xianglong has become a subsidiary of the company and is included in the consolidated financial statements [3] Group 2 - The company has completed the disposal of all shares held under the 2022 employee stock ownership plan, totaling 45,975,000 shares, which represents 0.63% of the company's total share capital [9] - The employee stock ownership plan was initiated in 2022 and has undergone several adjustments and approvals throughout its duration [5][7][8] - The plan will now proceed to asset liquidation and distribution, and will be terminated as per the relevant regulations [9] Group 3 - The company has proposed to provide guarantees for its subsidiaries, with a total guarantee amount not exceeding 40 billion yuan for the year 2026 [10] - The guarantees are intended to support the normal production and operational activities of the company and its subsidiaries [10] - Specific contracts for pledging patent rights have been signed with China Construction Bank, providing guarantees of up to 5 million yuan for two subsidiaries [11][20] Group 4 - The first meeting of the 2025 employee stock ownership plan was held on December 26, 2025, with 83 out of 95 registered participants attending [28][29] - The meeting approved the establishment of a management committee to oversee the employee stock ownership plan, with all members elected from the participants [29][30] - The management committee has been granted authority to manage the plan's daily operations and make decisions regarding the distribution of benefits and other related matters [31][32]